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Introduction: The addition of plerixafor to G-CSF (P 1 G)
successfully mobilizes sufficient hemtopoietic stem cells (HSC) for
autologous stem cell transplantion (ASCT) in patients with non-
Hodgkin’s lymphoma (NHL). In this analysis, we compare 12-
month graft durability among NHL patients receiving P 1 G as
a front-line or rescue mobilization regimen.
Methodology:Patients enrolled in the Phase III study who failed
to mobilize $2  106 CD341 cells/kg could enter into the rescue
arm of the study and receive P 1 G. Following a rest period of $7
days, patients were re-mobilized with G-CSF (10 mcg/kg/day) for
four days, and on the evening of day four, plerixafor (240 mcg/kg
SQ) was administered. On day five, all patients received a morning
dose of G-CSF before apheresis. The apheresis was a 3 volume 6
10% apheresis. Patients continued to receive P 1 G followed by
daily apheresis for up to four days or until $5  106 CD341
cells/kg were collected. Graft durability was measured at 3, 6 and
12 months; grafts were considered durable if at least 2 of the 3 fol-
lowing criteria were met: platelet count .50,000/ml without trans-
fusion for at least 2 weeks prior to follow-up, hemoglobin level$ 10
g/dL with no erythropoietin support or transfusions for at least 1
month before follow-up, absolute neutrophil count .1,000/ml
with no G-CSF for at least 1 week before follow-up visit. Patients
who had disease progression or died with a stable graft were
censored.
Results: As reported before, 130/150 (87%) patients receiving
P 1 G as a front-line regimen and 37/62 (60%) receiving P 1 G
as a rescue regimen collected $2  106 CD341 cells/kg. 135 pa-
tients in the front-line group and 52 patients in the rescue group un-
derwent ASCT. Data to evaluate graft durability at 12-months were
available for 112/135 (83%) patients in the front-line group and
44/52 (85%) patients in the rescue group. At 12-months, the propor-
tion of patients that maintained a durable graft in the front-line
group was 98.2%. One patient had graft failure due to pre-existing
myelodysplastic syndrome and one patient had AML. Compara-
tively, based on laboratory and clinical criteria, 100% of rescue
patients maintained a durable graft at 12-months.Conclusion: These data demonstrate that the quality of the HSC
collected with P 1 G in the rescue arm resulted in graft durability
rates that were comparable to cells transplanted when P 1 G was
used as a front-line mobilization regimen among patients with
NHL.23
TREATMENT-RELATEDMORTALITY IN PATIENTSWITH AL AMYLOIDOSIS
UNDERGOING HIGH-DOSE MELPHALAN AND STEM CELL TRANSPLANTA-
TION: TREND OVER THE PAST 14 YEARS AT A SINGLE INSTITUTION
Sanchorawala, V., Skinner, M., Finn, K.T., Quillen, K., Seldin, D.C.
Boston University Medical Center, Boston, MA
AL amyloidosis is caused by a clonal plasma cell dyscrasia leading
to multisystem organ failure and death. Aggressive treatment of AL
amyloidosis with high dose intravenous melphalan followed by
autologous stem cell transplantation (HDM/SCT) is effective in
inducing hematologic remissions and in extending survival. How-
ever, HDM/SCT is a challenging treatment for patients with AL
amyloidosis, given their multisystem disease. Morbidity and mor-
tality are associated with all phases of HDM/SCT: during stem
cell mobilization and collection, during post-treatment myelosup-
pression, and following hematopoietic engraftment. Between 7/94
and 7/08, 496 HDM/SCT were performed for patients with AL
amyloidosis, (median age5 56, range 28–80), at Boston University
Medical Center. Treatment-related mortality is defined as deaths
during stem cell mobilization and collection (SCMC) phase as
well as within 100 days after SCT. Overall treatment-related mor-
tality was 12% (58/496). Of the 58 deaths, 11 (2%) occurred during
the stem cell mobilization and collection phase of treatment, while
47 (9%) occurred within 100 days after SCT. Deaths during SCMC
were associated with arrhythmia (n 5 1), irreversible congestive
heart failure (n 5 2), refractory hypotension (n 5 3), myocardial
infarction due to small vessel amyloid disease (n 5 1), GI bleeding
(n5 3) and pulmonary embolism (n5 1). There were 5 deaths dur-
ing the stem cell infusion procedure. There were additional 42
deaths fromD1 1 toD1 100 after SCT.Deaths during this period
were associated with sepsis (33%), cardiac arrhythmia (26%) and
bleeding complications (10%). Overall treatment-related mortality
was 14% (52/371) during the period from 7/94 to 7/04, the first de-
cade of HDM/SCT for patients with AL amyloidosis. However,
overall treatment-related mortality has improved to 5% (6/125)
during the period from 8/04 to 7/08. Improvement in treatment-re-
lated mortality rate over the past 14 years may be due to improved
patient selection, to improvement in supportive care and to the cu-
mulative experience of the treating multidisciplinary team mem-
bers. In summary, HDM/SCT in AL amyloidosis presents unique
challenges. Both clinicians and patients must be prepared for
both the usual and unusual toxicities that may occur. Treatment-re-
lated mortality can be expected to be greater at centers with limited
experience with HDM/SCT for AL amyloidosis, compared with
centers that focus on this complex disease.GRAFT PROCESSING
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EX VIVO EXPANSION OF HUMAN CORD BLOOD PROGENITOR CELLS
WITH THE NOTCH LIGANDDELTA1 RESULTS IN RAPIDMYELOID RECON-
STITUTION IN VIVO FOLLOWINGMYELOABLATIVE CORD BLOOD TRANS-
PLANTATION
Delaney, C.1,2, Brashem-Stein, C.1, Voorhies, H.1, Gutman, J.1,3,
Heimfeld, S.1, Bernstein, I.D.1,2 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 2University of Washington School of Medicine, Seattle,
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We herein report results of the first 8 patients with leukemia en-
rolled in a phase I study evaluating the safety and potential efficacy
of cord blood (CB) progenitors cultured in the presence of the
Notch ligand, Delta1. Following a myeloablative preparative reg-
imen, patients received a CBU followed by a second unit that was
expanded ex vivo. Median age and weight of the patients enrolled
is 26 years (range 3 to 43) and 53 kg (16 to 76). After culture, the
average CD34 fold increase was 135 (41 to 382) with an average
total nucleated cell (TNC) fold increase of 570 (146 to 1496).
